# US 2017/0253664 A2 · Dual targeting of tafi and pai-1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253664 A2
- Document ID: US20170253664A2
- Status: Published application
- Kind: A2
- Application number: 15/117,027
- Filed: 2015-02-09
- Published: 2017-09-07
- Earliest claimed: 2014-02-07
- Assignees: Katholieke Universiteit Leuven; Inserm (Institut National De La Sante Et De La Recherche Medicale); Universite de Caen Basse Normandie; Centre Hospitalier Universitaire de Caen
- Applicants: Katholieke Universiteit Leuven; INSERM (Institut National de la Santé et de la Recherche Médicale); Université de Caen Basse Normandie; Centre Hospitalier Universitaire de Caen
- Inventors: Paul DECLERCK; Simon DE MEYER; Nick GEUKENS; Ann GILS; Marina RUBIO; Denis VIVIEN; Tine WYSEURE
- Web page: https://patentgrep.com/patent/US20170253664A2

## CPC

- C07K 16/38: against protease inhibitors of peptide structure
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2800/22: Haematology
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method of treating or preventing an acute thrombotic disorder in a patient, comprising the step of administering a bispecific antibody against TAFI and PAI-1, wherein said antibody comprises
a. a first targeting domain that specifically binds to Thrombin Activatable Fibrinolysis Inhibitor (TAFI) and comprises complementary determining regions (CDRs) represented by the amino acid sequences SEQ ID NO:1 of CDR1H, SEQ ID NO:2 of CDR2H, SEQ ID NO:3 of CDR3H, SEQ ID NO:4 of CDR1L, SEQ ID NO:5 of CDR2L, and SEQ ID NO:6 of CDR3L, and
b. a second targeting domain that specifically binds to Plasminogen Activator Inhibitor-1 (PAI-1) and comprises complementary determining regions (CDRs) represented by SEQ ID NO:7 of CDR1H, SEQ ID NO:8 of CDR2H, SEQ ID NO:9 of CDR3H, SEQ ID NO:10 of CDR1L, SEQ ID NO:11 of CDR2L and SEQ ID NO:12 of CDR3L.

### Claim 21 (depends on 20)

The method according to claim 20, wherein
a. said first targeting domain that binds to Thrombin Activatable Fibrinolysis Inhibitor (TAFI) comprises a VH region represented by an amino acid sequence that is at least 80% identical to SEQ ID NO:13 and a VL region represented by an amino acid sequence that is at least 80% identical to SEQ ID NO:14 and comprises complementary determining regions (CDRs) represented by the amino acid sequences SEQ ID NO:1 of CDR1H, SEQ ID NO:2 of CDR2H, SEQ ID NO:3 of CDR3H, SEQ ID NO:4 of CDR1L, SEQ ID NO:5 of CDR2L, and SEQ ID NO:6 of CDR3L; and
b. said second targeting domain that binds to Plasminogen Activator Inhibitor-1 (PAI-1) and comprises a VH region represented by an amino acid sequence that is at least 80% identical to SEQ ID NO:15 and a VL region represented by an amino acid sequence that is at least 80% identical to SEQ ID NO:16, and comprises complementary determining regions (CDRs) represented by SEQ ID NO:7 of CDR1H, SEQ ID NO:8 of CDR2H, SEQ ID NO:9 of CDR3H, SEQ ID NO:10 of CDR1L, SEQ ID NO:11 of CDR2L and SEQ ID NO:12 of CDR3L.

### Claim 22 (depends on 20)

The method according to claim 20,
wherein said first targeting domain that binds to Thrombin Activatable Fibrinolysis Inhibitor (TAFI) comprises a VH region represented by an amino acid sequence that is at least 90% identical to SEQ ID NO:13 and comprises a VL region represented by an amino acid sequence that is at least 90% identical to SEQ ID NO:14, and
wherein said second targeting domain that binds to Plasminogen Activator Inhibitor-1 (PAI-1) comprises a VH region represented by an amino acid sequence that is at least 90% identical to SEQ ID NO:15 and comprises a VL region represented by an amino acid sequence that is at least 90% identical to SEQ ID NO:16.

### Claim 23 (depends on 20)

The method according to claim 20,
wherein said first targeting domain that binds to Thrombin Activatable Fibrinolysis Inhibitor (TAFI) comprises a VH region represented by an amino acid sequence that is at least 95% identical to SEQ ID NO:13 and comprises a VL region represented by an amino acid sequence that is at least 95% identical to SEQ ID NO:14, and
wherein said second targeting domain that binds to Plasminogen Activator Inhibitor-1 (PAI-1) comprises a VH region represented by an amino acid sequence that is at least 95% identical to SEQ ID NO:15 and comprises a VL region represented by an amino acid sequence that is at least 95% identical to SEQ ID NO:16.

### Claim 24 (depends on 20)

The method according to claim 20,
wherein said first targeting domain that binds to Thrombin Activatable Fibrinolysis Inhibitor (TAFI) comprises a VH region represented by an amino acid sequence that is at least 98% identical to SEQ ID NO:13 and comprises a VL region represented by an amino acid sequence that is at least 98% identical to SEQ ID NO:14, and
wherein said second targeting domain that binds to Plasminogen Activator Inhibitor-1 (PAI-1) comprises a VH region represented by an amino acid sequence that is at least 98% identical to SEQ ID NO:15 and comprises a VL region represented by an amino acid sequence that is at least 98% identical to SEQ ID NO:16.

### Claim 25 (depends on 20)

The method according to claim 20, wherein said bispecific antibody is humanized.

### Claim 26 (depends on 20)

The method according to claim 20, for treating brain lesions in an acute thrombotic disorder.

### Claim 27 (depends on 20)

The method according to claim 20, wherein the acute thrombotic disorder is selected from the group consisting of, acute peripheral arterial occlusion, middle cerebral artery occlusion (MCAO), and thromboembolism such as deep vein thromboembolism and lung embolism.

### Claim 28 (depends on 20)

The method according to claim 20, in a combination treatment with tPA.

### Claim 29 (depends on 20)

The method according to claim 20, wherein said treatment is performed without administration of tPA, prior, together of after the administration of the bispecific antibody.

### Claim 30 (depends on 20)

The method according to claim 20, wherein said acute thrombotic disorder is characterized by presence of a platelet-rich blood clot.
